PCN Insights, News, Videos, and More

Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...

The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.

Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.

In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.

In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.

Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.

In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.

In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.

In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.